Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiology | 23 | 2023 | 574 | 2.170 |
Why?
|
| Cardiovascular Diseases | 18 | 2022 | 2307 | 1.560 |
Why?
|
| American Heart Association | 18 | 2023 | 349 | 1.540 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2022 | 852 | 1.140 |
Why?
|
| Hyperlipidemias | 7 | 2022 | 237 | 1.020 |
Why?
|
| Research Report | 5 | 2021 | 144 | 0.840 |
Why?
|
| Anticholesteremic Agents | 8 | 2022 | 256 | 0.820 |
Why?
|
| Primary Prevention | 2 | 2021 | 243 | 0.790 |
Why?
|
| Chest Pain | 5 | 2021 | 172 | 0.760 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2020 | 352 | 0.690 |
Why?
|
| Cholesterol | 5 | 2021 | 681 | 0.660 |
Why?
|
| Practice Guidelines as Topic | 9 | 2021 | 2430 | 0.620 |
Why?
|
| Cholesterol, LDL | 7 | 2022 | 583 | 0.620 |
Why?
|
| Aspirin | 1 | 2020 | 392 | 0.580 |
Why?
|
| Societies, Medical | 6 | 2021 | 1349 | 0.540 |
Why?
|
| Medication Adherence | 5 | 2022 | 520 | 0.540 |
Why?
|
| Consensus | 12 | 2022 | 1116 | 0.520 |
Why?
|
| Secondary Prevention | 3 | 2021 | 322 | 0.510 |
Why?
|
| Ezetimibe | 4 | 2022 | 97 | 0.500 |
Why?
|
| Advisory Committees | 5 | 2019 | 209 | 0.480 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 630 | 0.460 |
Why?
|
| Hypercholesterolemia | 4 | 2018 | 269 | 0.430 |
Why?
|
| Evidence-Based Medicine | 5 | 2021 | 1060 | 0.400 |
Why?
|
| United States | 30 | 2023 | 16066 | 0.390 |
Why?
|
| Atherosclerosis | 4 | 2022 | 957 | 0.350 |
Why?
|
| Coronary Artery Disease | 4 | 2021 | 946 | 0.330 |
Why?
|
| Awards and Prizes | 1 | 2010 | 88 | 0.330 |
Why?
|
| Diabetes Mellitus | 3 | 2022 | 1076 | 0.330 |
Why?
|
| Coronary Disease | 2 | 2010 | 783 | 0.310 |
Why?
|
| Hypertension | 3 | 2022 | 1624 | 0.310 |
Why?
|
| Myocardial Infarction | 2 | 2010 | 1304 | 0.290 |
Why?
|
| Risk Reduction Behavior | 4 | 2021 | 223 | 0.280 |
Why?
|
| Algorithms | 4 | 2021 | 3925 | 0.280 |
Why?
|
| Heart Valve Diseases | 2 | 2021 | 197 | 0.280 |
Why?
|
| Guideline Adherence | 2 | 2010 | 649 | 0.270 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 613 | 0.260 |
Why?
|
| Registries | 3 | 2021 | 2253 | 0.230 |
Why?
|
| Medication Therapy Management | 3 | 2018 | 36 | 0.220 |
Why?
|
| Hypolipidemic Agents | 2 | 2008 | 190 | 0.220 |
Why?
|
| Aortic Diseases | 2 | 2023 | 195 | 0.220 |
Why?
|
| Dyslipidemias | 2 | 2021 | 244 | 0.210 |
Why?
|
| Military Medicine | 1 | 2021 | 54 | 0.190 |
Why?
|
| Cardiovascular System | 1 | 2022 | 151 | 0.190 |
Why?
|
| Diet Therapy | 1 | 2021 | 53 | 0.190 |
Why?
|
| Heart Valves | 1 | 2021 | 62 | 0.190 |
Why?
|
| Nutrition Policy | 1 | 2021 | 109 | 0.180 |
Why?
|
| Hypertriglyceridemia | 1 | 2021 | 114 | 0.180 |
Why?
|
| Humans | 47 | 2023 | 272087 | 0.180 |
Why?
|
| Expert Testimony | 1 | 2020 | 85 | 0.170 |
Why?
|
| Risk Factors | 9 | 2021 | 18051 | 0.170 |
Why?
|
| Lipids | 2 | 2022 | 661 | 0.170 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 118 | 0.170 |
Why?
|
| Deprescriptions | 1 | 2019 | 25 | 0.170 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2021 | 177 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2020 | 1435 | 0.160 |
Why?
|
| Inappropriate Prescribing | 1 | 2019 | 52 | 0.160 |
Why?
|
| Risk Assessment | 7 | 2021 | 6885 | 0.160 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 1243 | 0.140 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2016 | 78 | 0.130 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2021 | 487 | 0.130 |
Why?
|
| Cholesterol, HDL | 2 | 2010 | 371 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2020 | 747 | 0.130 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2015 | 58 | 0.130 |
Why?
|
| Pharmacists | 1 | 2015 | 97 | 0.120 |
Why?
|
| Lower Extremity | 1 | 2017 | 284 | 0.120 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2015 | 107 | 0.120 |
Why?
|
| Peripheral Arterial Disease | 1 | 2017 | 272 | 0.110 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2016 | 142 | 0.110 |
Why?
|
| Anticoagulants | 2 | 2015 | 792 | 0.110 |
Why?
|
| Coronary Angiography | 1 | 2016 | 568 | 0.110 |
Why?
|
| Postal Service | 1 | 1992 | 17 | 0.110 |
Why?
|
| Pharmaceutical Services | 1 | 1992 | 36 | 0.110 |
Why?
|
| Consumer Behavior | 1 | 1992 | 46 | 0.110 |
Why?
|
| Aged | 10 | 2022 | 73517 | 0.100 |
Why?
|
| Health Policy | 1 | 2015 | 281 | 0.100 |
Why?
|
| Aortic Valve | 1 | 2015 | 484 | 0.100 |
Why?
|
| Disease Management | 2 | 2015 | 1113 | 0.100 |
Why?
|
| Managed Care Programs | 2 | 2022 | 84 | 0.090 |
Why?
|
| Observational Studies as Topic | 2 | 2021 | 148 | 0.090 |
Why?
|
| Biomarkers | 5 | 2021 | 5115 | 0.090 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2016 | 369 | 0.090 |
Why?
|
| Global Health | 2 | 2019 | 692 | 0.090 |
Why?
|
| Achievement | 1 | 2010 | 40 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2015 | 830 | 0.080 |
Why?
|
| Health Personnel | 1 | 2015 | 654 | 0.080 |
Why?
|
| Patient Care | 1 | 2010 | 151 | 0.080 |
Why?
|
| Health Care Surveys | 1 | 2010 | 425 | 0.080 |
Why?
|
| Program Evaluation | 1 | 2010 | 612 | 0.070 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 752 | 0.070 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 534 | 0.070 |
Why?
|
| Ambulatory Care Facilities | 1 | 2010 | 302 | 0.070 |
Why?
|
| Triglycerides | 1 | 2010 | 622 | 0.070 |
Why?
|
| Hospitals | 1 | 2010 | 493 | 0.070 |
Why?
|
| Retrospective Studies | 7 | 2022 | 39831 | 0.070 |
Why?
|
| Medicare | 2 | 2022 | 935 | 0.070 |
Why?
|
| Female | 9 | 2023 | 149288 | 0.070 |
Why?
|
| Treatment Outcome | 7 | 2021 | 33909 | 0.060 |
Why?
|
| Cholesterol, VLDL | 1 | 2004 | 18 | 0.060 |
Why?
|
| Middle Aged | 5 | 2020 | 90460 | 0.060 |
Why?
|
| Comorbidity | 2 | 2021 | 2439 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 2681 | 0.050 |
Why?
|
| Male | 6 | 2020 | 129088 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2010 | 918 | 0.050 |
Why?
|
| Multimorbidity | 1 | 2022 | 20 | 0.050 |
Why?
|
| Adult | 4 | 2021 | 81933 | 0.050 |
Why?
|
| United States Department of Defense | 1 | 2021 | 10 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2021 | 61 | 0.050 |
Why?
|
| Protective Factors | 1 | 2021 | 108 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 31066 | 0.050 |
Why?
|
| Committee Membership | 1 | 2020 | 4 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 5001 | 0.050 |
Why?
|
| Patient Care Management | 1 | 2021 | 94 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2000 | 128 | 0.040 |
Why?
|
| Aorta | 1 | 2023 | 684 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2021 | 356 | 0.040 |
Why?
|
| Angina, Unstable | 1 | 1998 | 72 | 0.040 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2000 | 229 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2021 | 663 | 0.040 |
Why?
|
| Sequestering Agents | 1 | 2017 | 2 | 0.040 |
Why?
|
| Drug Prescriptions | 2 | 2008 | 322 | 0.040 |
Why?
|
| Thromboembolism | 1 | 1998 | 153 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2022 | 620 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2021 | 691 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2018 | 160 | 0.040 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 327 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2021 | 680 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2010 | 9500 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2021 | 973 | 0.030 |
Why?
|
| Heparin | 1 | 1998 | 346 | 0.030 |
Why?
|
| Forecasting | 1 | 2019 | 706 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2017 | 251 | 0.030 |
Why?
|
| Drug-Eluting Stents | 1 | 2016 | 86 | 0.030 |
Why?
|
| Classification | 1 | 2015 | 40 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2015 | 130 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 309 | 0.030 |
Why?
|
| Morbidity | 1 | 2014 | 405 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 4513 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 605 | 0.020 |
Why?
|
| Pregnancy | 1 | 2023 | 8105 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 1966 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 5864 | 0.020 |
Why?
|
| Time Factors | 1 | 2021 | 13139 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 996 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 1327 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2006 | 371 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2008 | 711 | 0.010 |
Why?
|
| Logistic Models | 1 | 2008 | 3469 | 0.010 |
Why?
|
| Adolescent | 1 | 2021 | 32730 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 1992 | 5935 | 0.010 |
Why?
|
| Partial Thromboplastin Time | 1 | 1998 | 53 | 0.010 |
Why?
|
| Medical Records | 1 | 1998 | 447 | 0.010 |
Why?
|
| Hospital Costs | 1 | 1998 | 251 | 0.010 |
Why?
|
| Prognosis | 1 | 2014 | 22555 | 0.010 |
Why?
|
| Body Weight | 1 | 1998 | 1335 | 0.010 |
Why?
|
| Length of Stay | 1 | 1998 | 2015 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 1998 | 4400 | 0.000 |
Why?
|
| Texas | 1 | 1998 | 6440 | 0.000 |
Why?
|